|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00460 SIHUAN PHARM
Nominal 
1.670 -0.010 (-0.595%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 1,146,203 | 20.691% | 1,901,109 | 1,860,539 | 2,181,189 | 3,291,270 |
| Cost of Sales | (388,947) | 14.000% | (659,399) | (564,895) | (693,608) | (842,754) |
| Gross Profit | 757,256 | 24.443% | 1,241,710 | 1,295,644 | 1,487,581 | 2,448,516 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (1,727,119) | (131,297) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | 59,228 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (2,486) | -- | (15,226) | (53,621) | (80,875) | (158,581) | |
| Profit / (Loss) before Taxation | 156,924 | -- | (428,288) | (161,260) | (2,122,778) | 486,049 | |
| Taxation | (90,730) | 86.128% | (43,261) | (96,427) | (196,794) | (253,279) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | 36,296 | -- | |
| Non-controlling Interests | 36,409 | 5.429% | 254,887 | 203,670 | 368,358 | 183,739 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 102,603 | -- | (216,662) | (54,017) | (1,914,918) | 416,509 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 55,376 | -5.536% | 99,383 | 121,429 | 64,382 | (44,637) |
| Depreciation & Amortisation | -- | -- | 84,995 | 79,735 | 99,150 | 301,463 |
| Directors' Emoluments | -- | -- | 17,141 | 18,497 | 17,937 | 26,895 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 1.110 | -- | -2.340 | -0.580 | -20.520 | 4.420 |
| DPS (cts) | 0.990 | -- | 1.900 | 0.000 | 6.500 | 10.800 |
| Dividend Payout Ratio (%) | 89.189% | -- | -- | -- | -- | 244.344% |
| Cash flow per share ($) | -- | -- | 0.026 | 0.021 | 0.005 | 0.071 |
| NBV per share ($) | 0.477 | -- | 0.470 | 0.475 | 0.508 | 0.888 |
| Remarks: | Real time quote last updated: 11/09/2025 17:38 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 102,603 |
| %Change | -- |
| EPS / (LPS) | RMB 0.011 |
| NBV Per Share (¥) | RMB 0.477 |